NASDAQ:ENDP - Endo International Stock Price, News, & Analysis

Get Started

$9.70 -0.15 (-1.52 %)

(As of 01/20/2019 04:00 PM ET)

Previous Close$9.70

Today's Range$9.1450 - $9.8899

52-Week Range$5.27 - $18.50

Volume6.50 million shs

Average Volume3.44 million shs

Market Capitalization$2.18 billion

P/E Ratio2.53

Dividend YieldN/A

Beta0.92

Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets. The U.S. Branded Pharmaceuticals segment provides XIAFLEX for the treatment of Dupuytren's contracture and Peyronie's diseases; SUPPRELIN LA for central precocious puberty treatment; TESTOPEL, a long-acting implantable pellet for the treatment of central precocious puberty; NASCOBAL, a nasal spray to treat vitamin B12 deficiency; and AVEED for the treatment of hypogonadism. This segment also offers pain management products, such as PERCOCET, VOLTAREN Gel, and LIDODERM; TESTIM Gel for the treatment of endogenous testosterone; and FORTESTA Gel for hypogonadism treatment. The International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, and oncology. It sells its branded pharmaceuticals and generics directly to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors, as well as through wholesale drug distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland.

Receive ENDP News and Ratings via Email

Sign-up to receive the latest news and ratings for ENDP and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNASDAQ:ENDP

Previous Symbol

CUSIP29264F20

Webwww.endo.com

Phone011-353-1268-2000

Debt

Debt-to-Equity RatioN/A

Current Ratio1.13

Quick Ratio0.96

Price-To-Earnings

Trailing P/E Ratio2.53

Forward P/E Ratio3.55

P/E Growth3.54

Sales & Book Value

Annual Sales$3.47 billion

Price / Sales0.63

Cash Flow$8.3621 per share

Price / Cash Flow1.16

Book Value$2.17 per share

Price / Book4.47

Profitability

EPS (Most Recent Fiscal Year)$3.84

Net Income$-2,035,430,000.00

Net Margins-37.82%

Return on Equity1,348.52%

Return on Assets6.02%

Miscellaneous

Employees3,039

Outstanding Shares224,350,000

Market Cap$2.18 billion

OptionableOptionable

Endo International (NASDAQ:ENDP) Frequently Asked Questions

What is Endo International's stock symbol?

Endo International trades on the NASDAQ under the ticker symbol "ENDP."

How were Endo International's earnings last quarter?

Endo International PLC (NASDAQ:ENDP) released its quarterly earnings results on Thursday, November, 8th. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.12. The business had revenue of $745 million for the quarter, compared to analysts' expectations of $694.93 million. Endo International had a negative net margin of 37.82% and a positive return on equity of 1,348.52%. The firm's revenue for the quarter was down 5.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.91 earnings per share. View Endo International's Earnings History.

When is Endo International's next earnings date?

Endo International is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Endo International.

What guidance has Endo International issued on next quarter's earnings?

Endo International updated its FY18 earnings guidance on Thursday, November, 8th. The company provided earnings per share (EPS) guidance of $2.65-2.75 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.60. The company issued revenue guidance of $2.87-2.92 billion, compared to the consensus revenue estimate of $2.81 billion.Endo International also updated its FY 2018 guidance to $2.65-2.75 EPS.

What price target have analysts set for ENDP?

17 Wall Street analysts have issued twelve-month price objectives for Endo International's stock. Their forecasts range from $9.00 to $26.00. On average, they anticipate Endo International's share price to reach $16.0714 in the next twelve months. This suggests a possible upside of 65.7% from the stock's current price. View Analyst Price Targets for Endo International.

What is the consensus analysts' recommendation for Endo International?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 12 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endo International.

What are Wall Street analysts saying about Endo International stock?

Here are some recent quotes from research analysts about Endo International stock:

1. According to Zacks Investment Research, "Endo is in the process of redefining its business, given the persistent decline in the Generic business that is expected to face challenges. The focus now is on sterile injectables and Xiaflex. Demand for Xiaflex continues to be strong owing to high demand driven by increased demand in both Peyronie's disease and Dupuytren's contracture. Moreover, Endo has centralized and streamlined its global supply chain, quality and compliance organization in order to create a more cohesive and efficient structure to support both its generics and branded businesses. Endo is working to expand the drug’s label. However, huge level of debt is a concern. Moreover, response rates from the CCH trials weren’t impressive either. Shares have outperformed the industry in the last twelve months.." (1/17/2019)
2. Canaccord Genuity analysts commented, "We view Athenex’s compounded vasopressin launch today as more headline risk than an actual financial hit to Endo’s near-term results. We expect Endo to restart litigation with FDA regarding compounding guidance and we’d also expect patent litigation against Athenex that could potentially enjoin sales of the compounded product. While ENDP shares have had strong momentum of late, we remain concerned that little events like these – along with broader opioid and product litigation – could dent that momentum. As such, we maintain our HOLD rating on ENDP shares." (8/13/2018)
3. Cantor Fitzgerald analysts commented, ". We are raising our 12 month PT for ENDP shares to $12 from $7. The increase in our PT is driven by multiple expansion (from 8x to 9x 2019 EV/EBITDA versus 10x for the comps). We think this is deserved since generic drug pricing has stabilized for ENDP, according to the company, and we are optimistic that ENDP could report positive data for CCH to treat cellulite as early as the end of this year versus its official guidance of 2019. The following points support our view." (7/23/2018)

Has Endo International been receiving favorable news coverage?

Media headlines about ENDP stock have trended neutral this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Endo International earned a daily sentiment score of 0.1 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.

Are investors shorting Endo International?

Endo International saw a decrease in short interest in December. As of December 14th, there was short interest totalling 17,687,176 shares, a decrease of 13.1% from the November 30th total of 20,345,329 shares. Based on an average trading volume of 3,200,191 shares, the days-to-cover ratio is currently 5.5 days. Currently, 8.8% of the shares of the stock are short sold. View Endo International's Current Options Chain.

Who are some of Endo International's key competitors?

Some companies that are related to Endo International include Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Nektar Therapeutics (NKTR), Ionis Pharmaceuticals (IONS), Jazz Pharmaceuticals (JAZZ), Loxo Oncology (LOXO), SAGE Therapeutics (SAGE), Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS) and Catalent (CTLT).

Who are Endo International's key executives?

Endo International's management team includes the folowing people:

Mr. Paul V. Campanelli, Pres, CEO & Director (Age 57)
Mr. Blaise Coleman, Exec. VP & CFO (Age 45)
Mr. Terrance J. Coughlin, Exec. VP & COO (Age 53)
Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 47)
Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 62)

Who are Endo International's major shareholders?

Endo International's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bowling Portfolio Management LLC (0.06%). Company insiders that own Endo International stock include Blaise Coleman, Matthew Joseph Maletta, Nancy J Hutson, Paul Campanelli, Roger H Kimmel, Terrance J Coughlin and William P Montague. View Institutional Ownership Trends for Endo International.

Which institutional investors are buying Endo International stock?

ENDP stock was purchased by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC. Company insiders that have bought Endo International stock in the last two years include Blaise Coleman, Matthew Joseph Maletta, Paul Campanelli and Terrance J Coughlin. View Insider Buying and Selling for Endo International.

How do I buy shares of Endo International?

Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Endo International's stock price today?

One share of ENDP stock can currently be purchased for approximately $9.70.

How big of a company is Endo International?

Endo International has a market capitalization of $2.18 billion and generates $3.47 billion in revenue each year. The company earns $-2,035,430,000.00 in net income (profit) each year or $3.84 on an earnings per share basis. Endo International employs 3,039 workers across the globe.

What is Endo International's official website?

The official website for Endo International is http://www.endo.com.

How can I contact Endo International?

Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]

MarketBeat Community Rating for Endo International (NASDAQ ENDP)

Community Ranking:		2.7 out of 5 ( )
Outperform Votes:		839 (Vote Outperform)
Underperform Votes:		687 (Vote Underperform)
Total Votes:		1,526

MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.

This page was last updated on 1/20/2019 by MarketBeat.com Staff